Business
Joint broker update
Joint broker update.
About this update from Feedback Plc
[{"type":"text","content":"\n \nRNS Number : 5643T Feedback PLC 06 July 2018 \n\n6 July 2018\nFeedback plc\n(\"Feedback\" or the \"Company\")\n \nJoint broker update\n \nFeedback plc (AIM: FDBK), the specialist medical imaging technology company, announces that the Company's joint brokers are now solely Allenby Capital Limited and Peterhouse Corporate Finance Ltd. \n \nFor further information, please contact: \n\n\n\n\nFeedback plc\nDavid Crabb, Chief Executive Officer\nLara Mott, Investor Relations\n \n\n\nTel: 01954 718072\[email protected]\n\n\n\n\nAllenby Capital Limited (Nominated Adviser and Joint Broker)\nDavid Worlidge / Asha Chotai\n \n\n\nTel: 020 3328 5656\n\n\n\n\nPeterhouse Corporate Finance Ltd (Joint Broker)\n\n\n \n\n\n\n\nLucy Williams / Duncan Vasey\n \n\n\nTel: 020 7469 093\n\n\n\n\n \nNotes to editors\n \nAbout Feedback plc\n \nFeedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 50 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.\n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END MSCUSRWRWUABRRR\n ","length":3952,"tagName":"div"}]